Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106-16.

Article  Google Scholar 

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.

Article  PubMed  CAS  Google Scholar 

Kishi M, Miki A, Kamimura A, Okuda M, Matsumiya W, Imai H, et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med. 2023;12:5145.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fukuda Y, Notomi S, Shiose S, Maehara Y, Kiyohara K, Fujiwara K, et al. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population. Graefes Arch Clin Exp Ophthalmol. 2024;262:3971–8.

Article  PubMed  CAS  Google Scholar 

Matsumoto H, Hoshino J, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:83–90.

Article  PubMed  CAS  Google Scholar 

Mukai R, Honjo J, Tanaka K, Sekiryu T. Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment. BMC Ophthalmol. 2024;24:393.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13:8747.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. One-year outcomes and safety assessment of faricimab in treatment-naive patients with neovascular age-related macular degeneration in Japan. Sci Rep. 2024;14:11681.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : a randomized controlled trial. Adv Ther. 2020;37:1173–87.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123:51–9.

Article  PubMed  Google Scholar 

de Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I. Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects. Retina. 2016;36:881–8.

Article  PubMed  Google Scholar 

Marquis LM, Mantel I. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2020;258:1591–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13:21128.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:43–51.

Article  PubMed  CAS  Google Scholar 

Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652–6.

Article  PubMed  Google Scholar 

Veritti D, Sarao V, Gonfiantini M, Rubinato L, Lanzetta P. Faricimab in neovascular AMD complicated by pigment epithelium detachment: an AI-assisted evaluation of early morphological changes. Ophthalmol Ther. 2024;13:2813–24.

Article  PubMed  PubMed Central  Google Scholar 

Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, et al. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2024;8:360–6.

Article  PubMed  Google Scholar 

Sajiki AF, Kataoka K, Takeuchi J, Ota H, Nakano Y, Horiguchi E, et al. Clinical utility of swept-source optical coherence tomography angiography for the diagnosis of exudative maculopathy. Jpn J Ophthalmol. 2024;68:614–20.

Article  PubMed  Google Scholar 

Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69.

Article  PubMed  CAS  Google Scholar 

Machida A, Oishi A, Ikeda J, Kurihara J, Yoneda A, Tsuiki E, et al. Factors associated with success of switching to faricimab for neovascular age-related macular degeneration refractory to intravitreal aflibercept. Life (Basel). 2024;14(4):476.

PubMed  CAS  Google Scholar 

Todoroki T, Takeuchi J, Ota H, Nakano Y, Sajiki AF, Nakamura K, et al. Aqueous humor cytokine analysis in age-related macular degeneration after switching from aflibercept to faricimab. Invest Ophthalmol Vis Sci. 2024;65:15.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Takahashi H, Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Yoshida H, et al. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment. Sci Rep. 2024;14:9087.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822–32.

Article  PubMed  Google Scholar 

Rispoli M, Cennamo G, Antonio LD, Lupidi M, Parravano M, Pellegrini M, et al. Practical guidance for imaging biomarkers in exudative age-related macular degeneration. Surv Ophthalmol. 2023;68:615–27.

Article  PubMed  Google Scholar 

Sulzbacher F, Pollreisz A, Kaider A, Kickinger S, Sacu S, Schmidt-Erfurth U. Identification and clinical role of choroidal neovascularization characteristics based on optical coherence tomography angiography. Acta Ophthalmol. 2017;95:414–20.

Article  PubMed  Google Scholar 

Barth T, Reiners M, Zeman F, Greslechner R, Helbig H, Gamulescu MA. Anti-VEGF-therapy of fibrovascular and serous-vascularized pigment epithelial detachment in neovascular AMD: a retrospective five-year-analysis. Ophthalmologe. 2021;118:1255–63.

Article  PubMed  CAS  Google Scholar 

Canonica J, Foxton R, Garrido MG, Lin CM, Uhles S, Shanmugam S, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion. Front Cell Neurosci. 2023;17:1192464.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004;199:412–7.

Article  PubMed  CAS  Google Scholar